Quoted from the U.S. Department of Education's White House Initiative on Historically Black Colleges and Universities webpage.
Quoted from NIH's Stem Cell Information Glossary.
For additional information, see §4.1.13 of the NIH Grants Policy Manual.
For additional information, visit the Howard Hughes Medical Institute website.
Quoted from the NCI Dictionary of Cancer Terms.
For additional information, visit the HINTS webpage.
Quoted from the NCI Dictionary of Cancer Terms.
The Health and Medicine Division maintains the quality and soundness of our past health policy advice to the nation through rigorous study processes and the independent, objective analysis and advice for which the IOM and the National Academies have been known. HMD will continue to conduct consensus studies and convening activities through the six core boards that were part of the IOM.
Quoted from HealthCare.gov's Health insurance plan & network types: HMOs, PPOs, and more webpage.
Subtitle E: National Cancer Institute - Amends provisions stating the purpose of the National Cancer Institute to include rehabilitation from cancer. Makes miscellaneous changes to the special authorities of the Director of the National Cancer Institute relating to the provision of information to the public, patients, and physicians, incorporation of state-of-the-art cancer treatments into clinical practice, maintenance and operation of the International Cancer Research Data Bank, and the services of experts or consultants.
Amends provisions relating to grants for cancer research and demonstration centers to add control of cancer as one of their purposes.
Congressional Research Service summary quoted from the Congress.gov S.2889 - Health Omnibus Extension of 1988 webpage.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from Jobs@NIH.
Quoted from the U.S. Department of Educations's White House Initiative on Educational Excellence for Hispanics, Hispanic-Serving Institutions webpage.
The HSS is automatically populated by human subjects and clinical trial data entered by the principal investigator on the Human Subjects and Clinical Trial Information form in applications submitted for due dates of January 25, 2018 and beyond. This data is then made available to PIs and signing officials through a link that will be available on the eRA Commons Status screen and the Research Performance Progress Report (RPPR).
See the electronic Research Administration's Human Subjects System (HSS) — An Overview webpage.